Edit Target: 278
Almonertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is chemically designed and manufactured.
It is mainly used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. The drug is designed to overcome resistance to earlier-generation TKIs and to provide a more potent inhibition of EGFR signaling in tumors.